ArticlemBio2020
GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection.
Open access · goldAbstract read
In one paragraph
Article in mBio, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
1.5field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 79 citations in OpenAlex.
- Optimal Dose and Safety of Intravenous Favipiravir in Hospitalized Patients With COVID-19: A Dose-Escalating, Randomized Controlled Phase Ib Study.Clinical pharmacology and therapeutics · 2026Trial
- Exploring covalent inhibitors of SARS-CoV-2 main protease: from peptidomimetics to novel scaffolds.Journal of enzyme inhibition and medicinal chemistry · 2025Review
- Research Progress on the Structure and Function, Immune Escape Mechanism, Antiviral Drug Development Methods, and Clinical Use of SARS-CoV-2 MMolecules (Basel, Switzerland) · 2025Review
- Structural and virologic mechanism of the emergence of resistance to MProceedings of the National Academy of Sciences of the United States of America · 2024Article
- Review
- Breaking the Chain: Protease Inhibitors as Game Changers in Respiratory Viruses Management.International journal of molecular sciences · 2024Review
- Navigating the Complex Landscape of Ebola Infection Treatment: A Review of Emerging Pharmacological Approaches.Infectious diseases and therapy · 2024Review
- Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review.European journal of medicinal chemistry · 2023Review
- Development and validation of an LC-MS/MS method for quantification of favipiravir in human plasma.Journal of pharmaceutical and biomedical analysis · 2023Article
- Recent Advances in SARS-CoV-2 Main Protease Inhibitors: From Nirmatrelvir to Future Perspectives.Biomolecules · 2023Review
- Development of indolealkylamine derivatives as potential multi-target agents for COVID-19 treatment.European journal of medicinal chemistry · 2023Article
- Identification of SARS-CoV-2 MNature communications · 2023Article
- Cell Type-Specific Anti-Viral Effects of Novel SARS-CoV-2 Main Protease Inhibitors.International journal of molecular sciences · 2023Article
- Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure-Activity Relationship Insights and Evolution Perspectives.Journal of medicinal chemistry · 2022Review
- Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal.Journal of biomedical science · 2022Review
- The SARS-CoV-2 main protease (MMedComm · 2022Review
- Neutralization activity of sera/IgG preparations from fully BNT162b2 vaccinated individuals against SARS-CoV-2 Alpha, Beta, Gamma, Delta, and Kappa variants.Scientific reports · 2022Article
- Melatonin drugs inhibit SARS-CoV-2 entry into the brain and virus-induced damage of cerebral small vessels.Cellular and molecular life sciences : CMLS · 2022Article
- Recent advances in developing small-molecule inhibitors against SARS-CoV-2.Acta pharmaceutica Sinica. B · 2022Review
- Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and Protease-Glo luciferase assays.Acta pharmaceutica Sinica. B · 2022Article
Corrections and comments
- Commented on by
Authors and funding
16 authors at 4 institutions in 2 countries.
Shin-Ichiro HattoriDepartment of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Nobuyo Higshi-KuwataDepartment of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Jakka RaghavaiahDepartment of Chemistry, Purdue University, West Lafayette, Indiana, USA.
Debananda DasExperimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Haydar BulutExperimental Retrovirology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0003-0262-6296
David A DavisViral Oncology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Yuki TakamatsuDepartment of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.ORCID 0000-0001-7967-1576
Kouki MatsudaDepartment of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Nobutoki TakamuneKumamoto Innovative Development Organization, Kumamoto University, Kumamoto, Japan.
Naoki KishimotoDepartment of Environmental and Molecular Health Sciences, Faculty of Medical and Pharmaceutical Science, Kumamoto University, Kumamoto, Japan.
Tadashi OkamuraDepartment of Laboratory Animal Medicine, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Shogo MisumiDepartment of Environmental and Molecular Health Sciences, Faculty of Medical and Pharmaceutical Science, Kumamoto University, Kumamoto, Japan.
Robert YarchoanViral Oncology Section, HIV and AIDS Malignancy Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.ORCID 0000-0002-3057-1395
Kenji MaedaDepartment of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan.
Arun K GhoshDepartment of Chemistry, Purdue University, West Lafayette, Indiana, USA.
Hiroaki MitsuyaDepartment of Refractory Viral Infections, National Center for Global Health and Medicine Research Institute, Tokyo, Japan hiroaki.mitsuya2@nih.gov hmitsuya@hosp.ncgm.go.jp.ORCID 0000-0001-9274-3853
National Center for Global Health and Medicine · JPNational Institutes of Health · USKumamoto University · JPPurdue University West Lafayette · US
Funding
Design & Synthesis of Nonpeptide Protease InhibitorsR01AI150466 · NIAID · PURDUE UNIVERSITY · PI ARUN K GHOSH · 2023 to 2026
$2.4MDesign & Synthesis of Nonpeptide Protease InhibitorsR37AI150466 · NIAID · PURDUE UNIVERSITY · PI GHOSH, ARUN K · 2019 to 2020
$969kStudy of and development of antiviral drugs against SARS-CoV2 proteaseZIABC011945 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI YARCHOAN, ROBERT · 2020 to 2024
$864kNIAID NIH HHS HHSN272201700006CNIAID NIH HHS R01 AI150466NIAID NIH HHS R37 AI150466
Abstract
We assessed various newly generated compounds that target the main protease (M
Indexed as
Amino Acid SequenceAnimalsAntiviral AgentsBetacoronavirusChlorocebus aethiopsChloroquineCoronavirus 3C ProteasesCoronavirus InfectionsCOVID-19Cysteine EndopeptidasesIndolesModels, MolecularPandemicsPneumonia, ViralSARS-CoV-2Vero CellsAntiviral AgentsChloroquineCoronavirus 3C ProteasesCysteine EndopeptidasesIndolesViral Nonstructural Proteinsantiviral agentsCOVID-19main proteaseSARS-CoV-2
Identifiers
What Socratic holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.